NCT04732468View on ClinicalTrials.gov

COVID-19 Oral and Subcutaneous Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenovirus Platform in Healthy Volunteers in USA

PHASE1TerminatedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

February 24, 2021

Primary Completion Date

July 11, 2022

Study Completion Date

January 9, 2023

Conditions
Covid19
Interventions
BIOLOGICAL

hAd5-S-Fusion+N-ETSD (Suspension for injection)

The hAd5-S-Fusion+N-ETSD Vaccine is a human adenovirus serotype 5 (hAd5) vector with E1/E2b/E3 deletions expressing SARS-CoV-2 viral antigen spike fusion protein and nucleocapsid with an enhanced T-cell stimulation domain.

DRUG

hAd5-SFusion+ N-ETSD (Oral capsule)

The hAd5-S-Fusion+N-ETSD Vaccine is a human adenovirus serotype 5 (hAd5) vector with E1/E2b/E3 deletions expressing SARS-CoV-2 viral antigen spike fusion protein and nucleocapsid with an enhanced T-cell stimulation domain.

Trial Locations (2)

90245

Chan Soon - Shiong Institute for Medicine, El Segundo

92663

Hoag Memorial Hospital Presbyterian, Newport Beach

Sponsors

Lead Sponsor

ImmunityBio, Inc.
All Listed Sponsors
lead

ImmunityBio, Inc.

INDUSTRY